Close Menu

NEW YORK – Proteomics firm Seer said on Tuesday that it has spun out a new healthcare company, PrognomIQ, supported by an initial $55 million financing round.

The new company will use Seer's Proteograph proteomic platform along with other omics data to develop and commercialize clinical tests for cancer and other diseases.

The financing round was led by venture capital fund aMoon, with participation from existing Seer investors including Fidelity Management and Research, Invus, Maverick Ventures, Emerson Collective, Wing VC, and new investors including Bruker.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

AstraZeneca has released its coronavirus vaccine trial protocol, according to the New York Times.

Time magazine looks into how liquid biopsies are changing cancer care.

According to the Guardian, more than 150 countries have signed on to a global SARS-CoV-2 vaccine plan.

In PNAS this week: similar muscle protein patterns across hypertrophic cardiomyopathy phenotypes, analysis of gene expression and brain anatomy in major depression, and more.

Oct
14
Sponsored by
Inivata

Circulating tumor DNA (ctDNA) can allow clinicians and researchers to better understand which patients are at high risk of recurrence and should be offered intensified chemotherapy or selected for clinical trials.

Oct
29
Sponsored by
Illumina

Illumina’s BaseSpace Sequence Hub (BSSH) supports primary and secondary analysis of massively parallel sequencing data and can be applied to gene panel data that is generated as part of a clinical cancer assay performed in a pathology lab.